Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a report released on Monday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Price Performance

Shares of NYSE SENS opened at $0.34 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. The company has a market capitalization of $178.32 million, a PE ratio of -2.40 and a beta of 0.79. The stock’s 50 day moving average price is $0.38 and its 200-day moving average price is $0.42. Senseonics has a twelve month low of $0.32 and a twelve month high of $0.75.

Senseonics (NYSE:SENS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The business had revenue of $4.87 million for the quarter, compared to analysts’ expectations of $4.86 million. On average, equities analysts anticipate that Senseonics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Senseonics

Several institutional investors and hedge funds have recently bought and sold shares of SENS. State Board of Administration of Florida Retirement System bought a new position in Senseonics during the first quarter worth about $91,000. Virtu Financial LLC purchased a new stake in shares of Senseonics during the 1st quarter valued at approximately $162,000. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after buying an additional 211,128 shares in the last quarter. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.